ANGO News and Press, AngioDynamics Inc. From 10/06/22

Fiscal Year 2023 First Quarter Highlights Net sales of $81.5 million increased 5.9% compared to the prior-year quarter Med Tech net sales of $22.8 million increased 29.6% Med Device net sales of $58.7 million decreased 1.1% Gross margin of 51....

Summary The hold thesis remains for AngioDynamics following its latest set of numbers and impeding macro-headwinds. Shares have shown high correlation to long-dated treasury yields in FY22 and this continues to drive returns for ANGO. Valuations are unsupportive when stripping...

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that it will report f...

Due to the current economic factors in play, mutual fund manager Vanguard expects the U.S. economy to grow by just 1.5% in 2022. For context, this is down significantly from its previous forecast of 3.5% GDP growth for this year. The less optimistic growth outlook has heavily weighed on...

Raymond James updated its list of analyst favorite stocks with a swap in the restaurant subsector. Analysts can only have one favorite idea among the stocks they cover rated Strong Buy or Outperform. Ruth's Hospitality Group ( NASDAQ: RUTH ) makes it onto the Analysts Cu...

AngioDynamics posted better sales growth in FQ4'22 as elective procedure counts continue to rebound, but margin pressures continue to weigh significantly. The company is building a sustainable core growth story, with multiple opportunities to gain share and grow addressable markets in...

AngioDynamics presents with deflationary tailwinds bought on by a softening in key materials used in its manufacturing process. Despite this, investors continue to reward low-beta, highly profitable names in FY22, two statistics where ANGO lags. ANGO's latest quarter illustrates t...

AngioDynamics said that its fiscal year 2023 earnings per share guidance is $0.01-$0.06, below consensus expectation of $0.08. The medical technology company focused on the body’s vascular system noted that its FY 2023 revenue estimate is $342M to $348M vs. consensus o...

AngioDynamics, Inc. (ANGO) Q4 2022 Earnings Conference Call July 12, 2022, 08:00 AM ET Company Participants Jim Clemmer - President and Chief Executive Officer Steve Trowbridge - Executive Vice President and Chief Financial Officer Conference Call Participants ...

Fiscal Year 2022 Fourth Quarter Highlights Net sales of $87.0 million increased 13.2% compared to the prior-year quarter Gross margin of 53.4% declined 170 basis points year over year GAAP loss per share of $0.16 and adjusted earnings per share of $0.01 ...